With the issuance of the Guidelines, the Philippines Food and Drug Administration (FDA) aims to simplify the requirements and processes for the initial, renewal, and variation applications of the License to Operate (LTO), re-engineer and streamline FDA’s processes, and automate its system in compliance with the provisions of RA 11032 on the maximum prescribed processing time depending on the complexity of the transaction.
Table of Content:
Rationale
Objectives
Scope and Coverage
Definition of Terms
General Guidelines
Specific Guidelines
Penalty Clause
Repealing Clause
Separability Clause
Effectivity
Request a Demo
Original regulatory document
